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ABSTRACT 
 
The physiological role of the neurotrophin nerve growth factor (NGF) has been characterized, 
since its discovery in the 1950s, first in the sensory and autonomic nervous system, then in 
central nervous, endocrine and immune systems. The biological function of the NGF is the 
maintenance and survival of the peripheral and central nervous systems, which makes them of 
great therapeutic interest for the treatment of a number of neurodegenerative diseases. 
Identifying the ligands which can enhance the effect of this growth factor can be very vital for 
using it as a pharmacological tool in the treatment of various CNS diseases like the Alzheimer’s 
Disease, Parkinson’s Disease, Glaucoma and advanced optic nerve atrophy and various 
peripheral neuropathies. The property of the NGF to promote neuronal regeneration can also be 
applied in neural tissue engineering applications. Molecular docking was performed by 
Autodock4.2 using Lamarckian Genetic Algorithm to identify the ligands with high binding 
affinity with the NGF receptor TrkA. The best docked ligands were further analyzed for their 
potential as drug candidates by predicting their ADME properties using online PreADMET tool. 
From the combined analysis of molecular docking and ADME properties, a group of ligands 
having similar structure were further investigated to reveal that their similar structure led to their 
similar binding affinities with the NGFR. Quantitative Structure-Analysis Relationship (QSAR) 
models were studied using oleanolic acid as base structure, and 2D and 3D QSAR mathematical 
models were generated by using VlifeMDS (Version 4.3) to predict the activities of new analogs. 
These models can also be used to design new analogs with better activities by modulating the 
structure based on the results obtained. 
Key words: Nerve Growth Factor, neuronal regeneration, docking, ADME, QSAR 
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1.1 NEURAL TISSUE ENGINEERING 
Neural tissue engineering is aimed at promoting nerve regeneration and repairing the damage 
caused to neurons of both the Peripheral Nervous System (PNS) and the Central Nervous 
System (CNS). Loss of function or injuries to neurons in the CNS and PNS can be caused 
due to strokes, trauma or neurodegenerative disorders. In the PNS, if the injuries are small 
the nerves can regenerate on their own, but large injuries require surgical treatments often 
involving grafts [1]. In CNS, nerves fail to regenerate on their own as the native cellular 
environment of the CNS inhibits regeneration of cells [2]. Thus, due to the difficulty of nerve 
cells to repair or regenerate on their own, neural tissue engineering has emerged as a 
promising attempt at nerve repair. Various approaches to neural tissue engineering have been 
adopted in the past like physical guidance of neurites (axons or dendrites), use of grafts and 
biomaterials [3]. Lately, the role played by neurotrophic factors in neural regeneration is 
being extensively studied, and the mechanisms by which neurotrophic factors promote the 
survival and process outgrowths of neurons have also been well characterized [4]. 
1.2 NEURODEGENERATIVE DISORDERS 
Neurodegenerative Disorders refer to a range of conditions that alter the structure, and also 
the function of neurons in the human brain. They include diseases like Alzheimer’s Disease 
(AD), Huntington’s Disease (HD), Glaucoma, Amyotrophic Lateral Sclerosis (ALS), 
Parkinson’s Disease (PD), etc. Most of these diseases are incurable as the neurons once 
damaged cannot repair or replace themselves. In AD, there occurs a selective loss of neurons 
in the cerebral cortex and certain regions below the cortex. It is characterized by extracellular 
amyloid plaques and intracellular tau protein tangles [5]. In PD, there is a loss of neurons 
present in the substantia nigra region notably altering the central component of the pars 
compacta. Mutations in the parkin protein produce a parkinsonian syndrome responsible for 
some genetic forms of PD. The innate features of PD are rigidity, rest tremor and 
bradykinesia [6-7].  
1.3 NERVE GROWTH FACTOR AND ITS RECEPTOR 
Nerve Growth Factor (NGF), the earliest neurotrophic factor to be discovered, is the best-
characterized member of the neurotrophin family. It was discovered almost fifty years ago by 
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Rita Levi Montalcini. The neurotrophin family is a group of functionally and structurally 
similar homodimeric proteins, that include NGF, brain-derived neurotrophic factor (BDNF), 
neurotrophin-3 (NT-3), neurotrophin-4/5 (NT-4/5), and neurotrophin-6 [8-11]. The central 
biological function of NGF is to facilitate the maintenance and survival of the neurons of the 
CNS and PNS, which instills great interest in them for treating neurodegenerative disorders 
[11-12].  
The structure of NGF monomer has two pairs of antiparallel β-strands that twist around each 
other to form the central part of an elongated molecule. On one end, there are three hairpin 
loops (L1,L2 and L4 in figure 1), and on the other there is a cysteine knot motif that secures 
the folds of the strands and stabilizes the molecule in this conformation. It’s biologically 
active form has two monomers that are arranged parallel to each other, forming a closely 
packed homodimer [12]. 
 
 
 
 
 
 
 
 
 
 
 
  
    Figure 1: Ribbon structure of NGF monomer 
NGF is known to control actively the synthesis of neuropeptides and neurotransmitters in 
sympathetic and sensory neurons. The cholinergic neurons in the basal forebrain complex 
(BFC) are highly dependent on NGF for their survival and basic functions like motivation, 
attention, arousal, consciousness, and memory. As BFC neurons are compromised in 
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Alzheimer’s disease (AD), NGF is considered to be a potential therapeutic factor for such 
neurodegenerative disorders [13-14]. 
The neurotrophins exercise their action by binding to two groups of receptors - the p75 
neurotrophin receptor, also known as the low-affinity neurotrophin receptor (LNGFR) and 
the Trk receptors. p75 binds to all the neurotrophins with almost the same affinity. There are 
three Trk receptors namely; TrkA which preferably binds to the NGF, TrkB which preferably 
binds to BDNF and NT-4/5 and TrkC which at binds to NT-3 [15-18]. The Trk receptors 
(receptor tyrosine kinases) dimerize to their extracellular portions upon binding to 
neurotrophins. This dimerization event causes several tyrosine residues present in the 
cytoplasmic domain of the receptors to undergo autophosphorylation, thereby activating the 
intracellular signal transduction pathway. The TrkA receptor interacts with NGF 
independently and mediates NGF signaling [19]. Thus to regulate NGF activity, the TrkA 
receptor (NGFR) can be modulated by identifying ligands that can act as NGF stimulators. 
Computer Aided Drug Discovery (CADD) can be used to identify active drug candidates and 
optimize lead molecules. 
1.4 OBJECTIVE 
To identify modulators of NGFR (TrkA) for neuronal regeneration in neurodegenerative 
disorders and for tissue engineering applications. 
1.4.1 To prepare a database of phytochemicals 
1.4.2 To prepare protein target  
1.4.3 To perform molecular docking of all the phytochemicals with the target protein for 
the identifying novel drug candidates  
1.4.4 To study ADME properties of the best docked ligands 
1.4.5 To generate and validate QSAR models 
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2.1 NEURODEGENERATIVE DISORDERS 
2.1.1 Alzheimer’s Disease 
Alzheimer’s disease is a neurodegenerative disorder that leads to decline in memory, 
language, problem-solving and other cognitive skills of the affected person. This happens 
because the neurons of the regions involved in cognitive skills like the cerebral cortex and 
subcortical regions have been damaged and lose their normal function. The neuronal damage 
eventually affects other parts of the brain responsible for basic bodily functions. In the later 
stages, AD progresses rapidly and is ultimately fatal. According to the Alzheimer’s 
Association Report published in 2015, an estimated 5.3 million Americans are affected by 
AD; of which 5.1 million are above the age of 65 years, and approximately 200,000 are 
below the age of 65 years. In 2013, official death certificates recorded 84,767 deaths due to 
AD, making it the sixth leading cause of deaths in the United States [20].  
In AD, the neurons of the Basal forebrain complex and the cerebral cortex lose their function 
or/and structure. AD is characterized by the occurrence of two aggregates – extracellular 
amyloid plaques and intracellular neurofibrillary tangles of hyperphosphorylated tau protein. 
The amyloid plaques are found to contain small toxic cleavage products (Aβ40 and Aβ42) of 
the amyloid precursor protein (APP). Many mechanisms for the neurodegeneration pathway 
in AD have been proposed. According to one of the suggested views, Aβ protofibrils 
stimulate microglia, triggering an inflammatory response and production of neurotoxic 
cytokines. Another mechanism suggests that tau protein tangles and amyloid aggregates relay 
adverse effects or harmful responses to neurons by disabling the dendritic and axonal 
transport. Another mechanism indicates Aβ injury is due to synaptic dysfunction and loss. 
Synaptic dysfunction is believed to contribute to loss in memory and other cognitive 
deficiencies in AD. Aβ may also cause undesired effects by binding to redox-reactive metals 
which lead to release of free radicals. Oxidative stress from mitochondrial dysfunction, 
caused by the blocking of respiratory complex I have also been indicated as a potential 
pathway [21-24].  
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2.1.2 Parkinson’s Disease 
Parkinson’s Disease is another severe neurodegenerative disorder that affects a person’s 
movements. In PD, the dopamine-producing neurons of the substantia nigra region are 
compromised as a result of which initially movement-related activities are impaired and 
gradually cognitive. The marker of PD is characterized by loss of neurons within the 
substantia nigra region that affect the central component of the pars compacta. α-synuclein-
immunoreactive inclusions known as Lewy bodies are the characteristic lesions of PD [25]. 
Although -synuclein was the first protein to be linked with familial PD, eventually various 
additional genetic loci were determined which can now be linked to the development of PD. 
For example, mutations and polymorphisms in UHCL1, the gene encoding ubiquitin 
carboxy-terminal hydrolase L1 (UCH-L1), are linked to PD. Also, autosomal mutations 
in PARK2, gene that encodes parkin protein, are the cause for up to half of the juvenile and 
early-onset parkinsonism [26]. 
2.2 ROLE OF NGF IN VARIOUS DISEASES 
NGF is produced in large volumes in the cortex, the pituitary gland, and the hippocampus. It 
is also produced in certain other areas like basal ganglia, spinal cord, thalamus and the retina. 
As we now know, NGF has a significant role to play in the survival, maintenance and 
functioning of neurons in PNS and the cholinergic neurons in the CNS. Given this critical 
role played by NGF, a large number of diseases (especially neuropathies and degenerative 
disorders) are associated with altered NGF levels or/and changed expression of its receptors.  
The cholinergic neurons of the basal forebrain complex (BFC), which are highly affected in 
the AD depend on NGF for their survival and proper functioning. It has been found that AD 
patients show reduced levels of NGF in BFC of their brain. It was concluded from rat 
models, that NGF administration reduced cholinergic neuron death and cholinergic atrophy 
in rats [27-28]. It is also now accepted based on experimentation, that NGF can act on the 
two characteristic hallmarks of AD - β-amyloid neurotoxicity and tau hyperphosphorylation. 
In Down’s Syndrome, another neurodegenerative disorder, a similar reduction in NGF levels 
in the BFC, like in AD, is observed [29]. Another disease called glaucoma, which is the most 
common cause of blindness, is marked by the degeneration of the retinal ganglion cell (RGC) 
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and optic nerve atrophy. Glaucoma can be considered a neurodegenerative disease as the 
RGCs are a type of specialized neurons that pick up visual information from photoreceptors 
and convey the signal to the brain. In glaucoma, the increased intraocular pressure reduces 
the NGF levels in the cerebrospinal fluid and lateral geniculate nucleus. Thus using NGF as a 
means to attenuate RGC degeneration is a potential strategy [30]. NGF can also be exploited 
as a therapeutic tool in the treatment of other neurodegenerative disorders like PD, ALS, and 
Huntington Disease etc. 
Apart from the neurodegenerative disorders, NGF is known to have many other clinical uses 
in other diseases. It has been observed from human pathologies and various animal models, 
that disease-associated peripheral neuropathies, like diabetes and HIV, could be linked to 
irregularities in the regulation of synthesis, transport and usage of NGF by PNS neurons. For 
example, diabetes is characterized by degeneration and loss of function of some types of PNS 
neurons and deficits in NGF transport [31]. NGF administration in animal models of diabetic 
neuropathies has shown to reverse the neuropathic symptoms by preserving the compromised 
PNS neurons and restoring their normal activity [32]. NGF also has an important role to play 
in the response to neuronal injury. Peripheral nerve injury is often followed by remarkable 
neuronal cell death in dorsal root ganglion (DRG). NGF controls the synthesis of 
neuropeptides and neurotransmitters in sensory neurons. This ability of NGF helps it to 
counteract the effect of nerve injury on the DRG cells. NGF administration has been 
observed to sustain axonal regeneration. NGF also acts as a regulatory factor for several non-
neuronal cells which express NGF receptors on their surface. NGF receptors are expressed in 
immune cells allowing NGF to control cell differentiation and modulating the immune 
response. NGF influences differentiation, survival and phenotypic features of hematopoietic 
stem cells, granulocytes, monocytes and lymphocytes. NGF is also produced and utilized in 
skin cells like keratinocytes, and NGF deregulation has been observed in skin ulcers [33].  
2.3 DATABASE OF PHYTOCHEMICALS 
Given the important role of NGF in various diseases, it can be considered as an efficient 
potential treatment strategy for the disorders mentioned above. Till date, NGF administration 
through intracerebroventricular (ICV) injections and NGF-based gene therapy have been 
used for the delivery of NGF to the affected sites. One another strategy can be to stimulate 
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the low levels of NGF in the affected areas to prompt regeneration and reinstate normal 
function of neurons by using external factors like ligands that can bind to the NGFR. For this, 
a database of phytochemicals with neuroprotective properties was created in this study using 
literature survey. Phytochemicals (ligands) that turn out to have a high binding affinity to the 
NGFR can be in turn used as pharmacological tools to promote NGF activity in various 
diseases.  
Table 1: Database of phytochemicals (first few of the 235 phytochemicals under study) 
PLANT PHYTOCHEMICALS SOURCE 
1. Turmeric curcumin, cineol, α-phellanderene, 
sabinene, curlone, ar-curcumene,  
a-phellandrene, b-caryophyllene, 
b-sesquiphellandrene, borneol,      
b-bisabolene, sesquiter, d-3-carene,  
zingiberene 
[A Touch of Turmeric: 
Examining an Ayurvedic 
Treasure: Prianca Madi Reddi et 
al] 
2. Brahmi 
(bacopa 
monnieri) 
brahmine, d-mannitol,  herpestine, 
hersaponin, beta-sitosterol, 
monnierin, stigmastarol, betulic 
acid 
[Neuroprotective potential of 
phytochemicals: G. Phani Kumar 
and Farhath Khanum] 
3. Centella 
asiatica 
asiaticoside, betulic acid, 
oxyasiaticoside, isobrahmic acid, 
centelloside, brahmic acid,  
brahmoside, madecassic acid, 
brahminoside, asiatic acid,  
thankunoside, isothankunoside 
[Neuroprotective potential of 
phytochemicals: G. Phani Kumar 
and Farhath Khanum] 
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4.Withania 
somnifera 
cuscohygrine, scopoletin, tropine, 
anahygrine, withasomnine,  
anaferine, withanine, somnine, 
isopelletierine, withananine, 
withananinine, somniferinine, 
pseudo-withanine, withaferine,  
somniferine, condensed tannins, 
visamine 
[Phytochemical and 
Pharmacological Profile of 
Withania somnifera Dunal -A 
Review: Qamar Uddin et al] 
5. Acorus 
calamus 
sesquiterpenes, flavonoids, α- and 
β-asarone, calamen, clamenol, 
calameon, acorine, eugenol, pinene, 
camphene,elemicine, calamendiol, 
cisisoelemicine, cis and trans 
isoeugenol, P-cymene, bgurjunene, 
α-selinene, β-cadinene, terpinen-4-
ol, camphor, calacorene, linalool, 
aterpineol, acorone, spathulenol, 
acrenone, acoragermacrone, 2-
deca-4,7 dienol, Acoradin,  
shyobunones, preisocalamendiol, 2, 
4, 5- trimethoxy benzaldehyde, 
galangin, 2, 5 dimethoxy 
benzoquinone. 
 
[Sweet flag (Acorus calamus 
Linn.): An incredible medicinal 
herb, Hashmat Imam et al] 
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CHAPTER 3: 
METHODS AND 
MATERIALS 
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3.1 BIOINFORMATICS TOOLS AND SOFTWARES 
1. National Centre for Biotechnology Information (NCBI) 
2. Protein Data Bank (PDB) 
3. UniProt 
4. PubChem 
5. PRODRG Server 
6. ArgusLab 
7. UCSF Chimera 
8. AutoDock 4.2 
9. Cygwin 
10. PreADMET 
11. ChemDraw 
12. VlifeMDS 4.3  
12.1 2D QSAR Module 
12.2 Molecular Alignment Module 
12.3 3D QSAR Module 
3.2 PROTEIN STRUCTURE RETRIEVAL 
The three dimensional crystal structure of the target protein (NGFR) was obtained from an 
online database- Protein Data Bank (http://www.rcsb.org/pdb/). To predict the active site of 
the protein and perform further docking studies, miscellaneous ligands were removed to 
obtain the isolated structure of the protein using Argus Lab Software. Other heteroatoms such 
as water, ions, etc. present in the protein model were removed too. The geometry and energy 
minimization of the protein were performed, and the optimized protein was saved in .pdb 
format.  
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Figure 2: Ribbon Structure of TrkA receptor (PDB ID:4AOJ) 
 
3.3 PROTEIN ACTIVE SITE PREDICTIONS: 
The active sites of target protein were identified from the literature on UniProt 
(http://www.uniprot.org/). The binding and active sites present in TrkA receptor were found 
to be Asp-399, Tyr-496, Lys-544, Asp-650, and Tyr-791. Asp-650, being the active site, was 
used as the center residue for grid box. 
3.4 PREPARATION OF DATABASE OF PHYTOCHEMICALS (LIGANDS): 
A database of plants with neuroprotective properties and their phytochemicals was prepared. 
A total of 235 phytochemicals from 26 plants were collected and their structures 
downloaded. The three dimensional structures of these phytochemicals were retrieved from 
PubChem database (http://pubchem.ncbi.nlm.nih.gov/). The .sdf files thus obtained were 
converted to PDB structure of the phytochemicals by using the online PRODRG Server 
(http://davapc1.bioch.dundee.ac.uk/cgi-bin/prodrg/run.html#DRGPOH.PDB). 
15 
 
 
Figure 3: Screenshot of oleanolic acid in PubChem 
 
3.5 MOLECULAR DOCKING: 
Docking is an efficient technique to predict the binding affinity and orientation of various 
ligands to a particular protein. Thus, the molecular docking of the NGF receptor TrkA 
(protein) and phytochemicals (ligands) was performed at the active site of the target protein 
using the AutoDock4.2 software (version 1.5.6). In Autodock, polar hydrogens were added to 
the protein model and Kollman charges were assigned to the protein structure. The ligand 
was added, and both the protein and ligand structures were saved in .pdbqt formats. The grid 
maps representing the proteins were calculated using autogrid and grid size was set to 
60*60*60 points, and it was fixed on the active site Asp-650. The resultant file was saved in 
.gpf format. Docking of ligand was carried out using Lamarckian Genetic Algorithm as the 
search function, and the final structure was saved as .dpf format.  
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Figure 4: Screenshot of fixing the grid on oleanolic acid while Docking in AutoDock 
 
3.6 CONVERSION OF .gpf AND .dpf FILES TO PDB FILES USING CYGWIN  
The .gpf and .dpf files generated from Autodock were then converted to .glg and .dlg files 
using the Cygwin command prompt. These files were further converted into PDB formats. 
These PDB formats are the docked structure of the protein and ligand which can be viewed in 
ArgusLab or Chimera. The .dlg file can be opened in a WordPad and the lowest binding 
energy and estimated inhibition constant of the ligands were tabulated. Lowest binding 
energy will signify the highest binding affinity to the target protein.  
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Figure 5: Screenshot of Cygwin command prompt 
 
3.7 ADME PREDICTIONS: 
A very important challenge in the drug discovery process is that more than half of the drugs 
in a drug discovery process fail to commercialize because of deficits in ADME and toxicity 
properties. Hence, early prediction of these properties are required these days to increase the 
success rate of lead molecules. The ligands having a good binding affinity with the NGFR 
were further examined for their ADME properties and toxicity as part of lead optimization. 
This was done using an online tool PreADMET (http://preadmet.bmdrc.org/ ). The structure 
of the ligand was submitted in the ADME worksheet, and the output file was saved. 
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Figure 6: Screenshot of PreADMET tool 
 
3.8 QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP (QSAR):  
QSAR is a method to understand the relationship between a molecule’s bioactivity and its 
structure. The bioactivity of a molecule is directly dependent on its structure, and thus 
molecules having similar structure tend to have similar activities. QSAR can, therefore, be 
used to design a mathematical model based on a group of analogs of a lead molecule that 
can predict the activity of other similar molecules.  
2D and 3D QSAR were performed using the VLife Molecular Design Suite (VLifeMDS) 
version 4.3. Thirty substituted oleanolic acid derivatives were taken and their activity data 
were given as the negative logarithm of inhibition constant (-log Ki). These activity data are 
used as the dependent variable for our QSAR studies.  
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Figure 7: Skeleton structure used for QSAR (oleanolic acid) 
 
Table 2: Oleanolic Acid derivatives with their corresponding activity 
S.NO. R1 R2 R3 R4 R5 B.E. 
(kcal/mol) 
Ki ACTIVITY 
(-log Ki) 
OA1 OH H H H CH3 -11 8.61 nM 8.064 
OA2 OH H H OH CH3 -11.42 4.28 nM 8.368 
OA3 OAc H H OH CH3 -14.39 28.18 pM 10.55 
OA4 OH =O OH CH3 -10.58 17.54 nM 7.756 
OA5 OAc OH H H CH3 -12.01 1.57 nM 8.804 
OA6 OMe OH H H CH3 -12.21 1.13 nM 8.947 
OA7 NH2 OH H H CH3 -10 46.86 nM 7.329 
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OA8 Cl OH H H CH3 -11.42 4.26 nM 8.37 
OA9 OH Cl H H CH3 -12.74 456.28 pM  9.341 
OA10 OH OMe H H CH3 -11.92 1.83 nM 8.737 
OA11 OH NH2 H H CH3 -11.03 8.27 nM 8.082 
OA12 OH OAc H H CH3 -12.28 988.85 pM 9.004 
OA13 OH H H OAc CH3 -11.27 5.50 nM 8.26 
OA14 OH H H NH2 CH3 -11.01 8.52 nM 8.069 
OA15 OH H H Cl CH3 -11.56 3.33 nM 8.477 
OA16 OH H H OMe CH3 -10.92 9.85 nM 8.006 
OA17 OH H H C2H5 CH3 -11.07 7.67 nM 8.115 
OA18 OH H H OH OEt -13.41 147.10 pM 9.832 
OA19 OH H H OH Cl -11.6 3.17 nM 8.499 
OA20 OH H H OH OAc -13.45 137.91 pM 9.86 
OA21 OH H H OH OMe -12.65 535.69 pM 9.271 
OA22 OH OH H OH OMe -12.11 1.33 nM 8.876 
OA23 OH OH H H NH2 -10.63 16.03 nM 7.795 
OA24 OH OH OH H OEt -13.63 102.04 pM 9.991 
21 
 
OA25 OH OH H OH OEt -13.72 87.53 pM 10.058 
OA26 OH OH H Cl OEt -13.76 81.45 pM 10.089 
OA27 OH H Cl OH OH -12.98 304.39 pM 9.516 
OA28 OH H Cl CH3 OAc -13.98 66.25 pM 10.178 
OA29 OH H CH3 CH3 OAc -14.56 21.41 pM 10.669 
OA30 OH H CH3 CH3 Cl -11.7 2.65 nM 8.576 
 
3.8.1 2D QSAR 
Various 2D molecular descriptors like Individual (like molecular weight, slogp, H-Acceptor 
count, Xlogp, H-donor count, rotatble bond count, smr etc.), chi, chiV, path count, path 
cluster, polar surface area were calculated. Alignment Inependent descriptors were 
calculated too. Invariable columns were removed, and Variable columns were used as the 
independent variables for the building the model. Most favourable test and training set were 
created using the Sphere Exclusion Method, which ensures that the points in both the sets 
are uniformly distributed w.r.t. chemical and biological space [34]. Seven molecules were 
selected as the test set and remaining twenty-two as the training set.  
Four different models were generated using two Variable Separation Methods (Stepwise 
Variable Selection, Simulated Annealing) and two Regression methods (Multiple, Partial 
Least Square). The models were analyzed, and all the output data and graphs were saved.   
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3.8.2 ALIGNMENT OF MOLECULES 
In a 2D QSAR model, the input data for building the model is independent for each 
molecule. However, in a 3D model the 3D descriptors like dipole moment, electrostatic and 
steric fields etc depend not only on individual molecular properties but the effect of each 
molecule on the others. Therefore, all the molecules in the data set for 3D QSAR need to be 
aligned with respect to each other. This helps in studying variations of each molecule with 
respect to the skeleton structure. Alignment of molecules was performed using the “Align 
Molecules” module of VLifeMDS version 4.3. Atom Selection Method was used, and the 
carbon atoms of the skeleton ring were set as the alignment atoms. The aligned molecules 
were saved and then opened in VLifeMDS by drag-n-drop to open simultaneously. 
3.8.3 3D QSAR 
3D QSAR was performed using the “3D QSAR” module of VLifeMDS software. 3D QSAR 
evaluates three-dimensional molecular fields and relates them to the activity of molecules. To 
build the 3D model, k-Nearest Neighbour method was used. In this method, a rectangular 
grid is generated around the set of aligned molecules. Molecular field energies are computed 
at the lattice points of the grid and are used as descriptors to establish the structure-activity 
relationship [35]. The electrostatic and steric fields were computed by applying the 
Gasteiger-Marsili charges and setting the dielectric constant as 1. The invariable columns 
were removed and the variable columns were used as the independent variable. Optimal test 
and training set were generated again using the Sphere Exclusion Method. 4 molecules were 
selected as the Data Set and the remaining 26 as the Training Set. The Unicolumn statistics 
like average, maximum, minimum etc of the activities of the Test and Training set were 
computed. The model was analyzed, and the output data and graphs were saved. 
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Figure 12: 3D Model – kNN method with Forward- Backward Stepwise Variable 
Selection Method 
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4.1 RETRIEVAL AND PREPARATION OF THE RECEPTOR 
The crystal structure of human TrkA receptor (high affinity NGFR) in complex with AZ-23 
inhibitor (PDB ID 4AOJ), having resolution of 2.75 A° was retrieved from the Protein Data 
Bank and the miscellaneous ligands, the inhibitor and water molecules were removed using 
ArgusLab. Energy minimization and geometry optimization of the receptor were also done 
using ArgusLab.  
 
Figure 13: The receptor protein after required modifications in ArgusLab 
4.2 DOCKING STUDIES 
In our efforts to identify ligands modulating the NGFR, we performed molecular docking of 
a list of ligands with the target protein. Docking was performed using AutoDock 4.2 using 
the Lamarckian Genetic Algorithm. Lower the energy of binding, higher is the binding 
affinity of the ligand for the protein. Ligands with binding energy less than or equal to -8.00 
kcal/mol are considered as the best compounds. We found that kaempferol-3-o-glucoside 
showed the highest binding affinity towards NGFR with a binding energy of -9.76 kcal/mol. 
Some other molecules like taraxerone, oleanolic acid, taraxerol, ursolic acid, alpha and beta- 
amyrin also showed significantly high binding affinity towards the target protein with 
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binding energies of -9.24 kcal/mol, -9.15 kcal/mol, -8.97 kcal/mol, -8.95 kcal/mol, -9.08 
kcal/mol -8.95 kcal/mol respectively.  
The docking result of ligands with the target protein are listed below :- 
Table 3: Docking results of ligands with B.E < -7.5 kcal/mol 
LIGANDS MIN. B.E. 
(kcal/mol) 
Ki 
kaempferol-3-glucoside  -9.76 70.59 nM 
Taraxerone -9.24 169.24 nM 
oleanolic acid -9.15 197.51 Nm 
alpha-amyrin -9.08 221.30 nM  
Taraxerol -8.97 267.71 nM 
ursolic acid -8.95 277.44 nM 
beta-amyrin -8.95 274.05 nM  
epigallocatechin gallate -8.93 283.11 nM  
Cycloeicosane -8.82 344.41 nM  
alpha sitosterol -8.78 369.51 nM  
kaempferol-3-rutinoside  -8.76 379.76 nM 
Hesperidin -8.62 476.50 nM  
Diosmetin -8.6 497.36 nM 
Luteolin -8.56 534.72 nM 
Stigmasterol -8.52 569.50 nM  
Quercetin -8.5 585.01 nM 
Eriodictyol -8.46 628.13 nM  
catechin gallate -8.4 700.69 nM  
Baicalin -8.39 704.76 nM  
Jatamansin -8.37 731.16 Nm 
gamma sitosterol -8.33 784.89 nM 
rosmariquinone (miltirone) -8.23 931.41 nM 
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Reserpine -8.2 972.55 nM  
beta sitosterol -8.19 984.40 nM 
Dihydroquercetin -8.18 1.02 μM 
Kaempferol -8.14 1.08 μM 
Rutin -8.12 1.11 μM  
carnosic acid -8.1 1.15 μM 
Ajmalicine -8.08 1.19 μM  
Wogonin -8.07 1.22 μM  
Tabersonine -8.03 1.30 μM  
ginkgolide A -8.01 1.34 μM  
Hispidulin -8.01 1.34 μM 
Catharanthine -7.95 1.49 μM  
Carnosol -7.94 1.51 μM 
Baicalein -7.92 1.57 μM  
Nomilin -7.9 1.61 μM  
Galangin -7.86 1.72 μM 
Myrcetin -7.82 1.87 μM  
quercetin 3-methyl ether -7.8 1.93 μM 
valerenic acid -7.74 2.13 μM  
ginkgolide B -7.74 2.11 μM  
chlorogenic acid -7.71 2.22 μM  
Apigenin -7.6 2.69 μM 
Taxifolin -7.57 2.82 μM  
ginkgolide J -7.57  2.84 μM  
Norwogonin -7.56 2.90 μM  
Oroxylin -7.55 2.92 μM  
Harmaline -7.53 3.05 μM 
Hydroxypinoresinol -7.53 3.02 μM  
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4.3 ADME RESULTS 
The ADME properties predictions were done using the online PreADMET server. The 
PreADMET server calculates the CACO2 (human colon adenocarcinoma) model, MDCK 
(Madin-Darby Canine Kidney) model, Human Intestinal Absorption (HIA) which provide a 
measure of absorption; and Skin Permeability and Blood-Brain Barrier (BBB) models which 
give a measure of distribution in the body system.  
Table 4: Optimum values of Absorption and Distribution Models 
 Low Absorption Moderate High 
CACO2 <4 nm/sec 4-70 nm/sec >70 nm/sec 
MDCK <25 nm/sec 25-500 nm/sec >500 nm/sec 
HIA <20 % 20-70 % >70 % 
 Low Distribution Moderate High 
BBB (Cbrain/Cblood) <0.1  0.1-2 >2 
Plasma-Protein Binding >90 %  <90 % 
 
Table 5: ADME Properties of ligands having high binding affinity to the target protein 
LIGAND CACO2 
(nm/sec) 
MDCK 
(nm/sec) 
HIA 
(%) 
SKIN 
PERMEABI-
LITY  
(log Kp) 
BBB PLASMA-
PROTEIN 
BINDING 
(%) 
Kaempferol-3-
glucoside 
11.1458 1.1475 25.1716 -4.6476 0.03500 57.5756 
Taraxerone 49.5959 0.1641 100 -1.9651 21.2078 100 
oleanic acid 21.8872 0.0439 95.9963 -2.3543 7.8792 100 
alpha-amyrin 49.0784 1.0017 100 -1.8331 18.3975 100 
Taraxerol 48.7377 0.1417 100 -1.8570 18.5142 100 
ursolic acid 22.0031 0.0449 96.0292 -1.5881 7.5231 100 
beta-amyrin 46.7500 0.1749 100 -2.2225 21.2500 100 
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epigallocatechin 
gallate 
12.0421 0.0446 20.7125 -3.9954 0.0875 100 
Cycloeicosane 22.1927 68.0213 100 -0.5025 20.4647 100 
alpha-sitosterol 52.6295 4.1754 100 -0.5928 19.9303 100 
k3rutinoside 9.1328 0.2510 6.2896 -4.5985 0.0293 42.3746 
Hesperidin 5.9216 0.0815 9.8828 -4.6202 0.0300 43.4520 
Diosmetin 7.0252 23.8531 88.1882 -4.1347 0.2011 90.1601 
Luteolin 4.5397 36.5205 79.4272 -4.2801 0.3676 99.7172 
Stigmasterol 52.3734 8.8572 100 -0.5934 19.8883 100 
Quercetin 3.4129 13.3528 63.4852 -4.4334 0.1727 93.2361 
Eriodictyol 4.5336 35.5683 77.4301 -4.3140 0.3802 100 
catechingallate 13.2124 0.0460 40.5818 -3.8897 0.1411 100 
Baicalin 11.5594 0.1477 32.4230 -4.3741 0.0252 75.6919 
Jatamansin 39.4601 3.4499 98.5170 -2.6101 0.1507 93.8556 
Gsitosterol 52.3734 8.8572 100 -0.5934 19.8883 100 
Miltirone 23.9684 89.6944 93.7125 -1.6150 10.0165 100 
Reserpine 35.0577 0.0436 89.7527 -4.7246 0.2252 54.3845 
Bsitosterol 52.3734 8.8572 100 -0.5934 19.8883 100 
dihydroquercetin 3.4231 9.5674 60.1637 -4.4261 0.1669 95.1644 
Kaempferol 9.5774 29.6119 79.4393 -4.3255 0.2861 89.6082 
Rutin 7.91267 0.3269 2.8612 -4.6667 0.0285 43.8979 
carnosic acid 20.7221 120.711 92.5232 -1.5304 4.1091 96.6142 
Ajmalicine 20.7542 5.1815 90.6079 -4.8837 1.4696 29.5477 
Wogonin 4.2822 152.119 93.0394 -3.3113 0.7246 90.4470 
Tabersonine 35.1299 6.3901 91.5681 -4.5715 2.69073 46.3189 
Ginkgolidea 20.6965 0.8771 64.7994 -4.8812 0.13814 49.2247 
Hispidulin 5.4632 32.2235 88.1840 -4.1299 0.1073 91.5559 
catharanthine 34.6456 37.9216 91.8445 -4.5271 5.2094 55.8748 
Carnosol 21.1724 144.317 92.5807 -2.6397 4.5820 97.5762 
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Baicalein 1.2802 101.909 88.1054 -4.1355 0.7708 98.9832 
Nomilin 25.4412 0.6416 94.4843 -3.3555 0.1102 66.6485 
Galangin 3.7059 79.4051 88.1226 -4.1908 0.6713 88.1221 
Myrcetin 0.9913 0.9913 40.9640 -4.5272 0.1103 96.7848 
Kaempferol-3-
methylether 
3.9330 32.8102 88.1926 -4.2555 0.3009 83.9814 
valerenic acid 15.1311 154.204 98.3301 -1.3518 0.9793 100 
Ginkgolideb 20.572 0.6127 40.3047 -5.0305 0.1193 41.2074 
chlorogenic acid 18.7316 4.267 17.5366 -3.9402 0.0372 41.4260 
Apigenin 10.5468 44.302 88.1228 -4.1457 0.5651 97.2534 
Taxifolin 3.42307 9.5674 60.1637 -4.4261 0.1669 95.1644 
Ginkgolidej 20.8757 0.6279 40.3047 -5.0421 0.1143 41.4346 
Norwogonin 2.0536 108.04 88.1095 -4.1254 0.8388 96.6339 
Oroxylin 1.7836 129.427 93.0362 -3.3254 0.1235 91.2836 
Harmaline 40.4085 307.684 90.9619 -4.4240 4.9845 72.7077 
Hydroxypinoresi
nol 
22.792 4.3395 89.6144 -4.1818 0.0942 69.8990 
 
The above table reveals that though kaempferol-3-glucoside is the best docked ligand, its 
ADME properties are relatively poor. Kaempferol-3-glucoside has low values of CACO2 and 
MDCK models indicating low oral absorption. It has a low value for Human intestinal 
absorption as well and low value of BBB indicates that it has low distribution to the Central 
Nervous System. However, the next set of molecules – taraxerone, oleanolic acid, taraxerol, 
alpha and beta-amyrin and ursolic acid were found to have high values for CACO2 and 
MDCK models. They even have high values of human intestinal absorption and BBB 
indicating high distribution to the Central Nervous System. Thus, these molecules could be 
lead compounds for targeting the NGFR.  
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4.4 QSAR STUDIES 
Biological activity of any compound is directly linked to its molecular structure. Hence, 
compounds with similar structure are expected to possess similar bioactivities. QSAR is a 
computational method to build a mathematical model that can help to predict the bioactivities 
so similar compounds. The mathematical model establishes a correlation between various 
molecular properties (descriptors) of a set of molecules with their experimentally known 
biological activity. 2D and 3D QSAR were performed with 30 oleanolic acid derivatives and 
various models were generated.  
4.4.1 2D QSAR 
Certain 2D descriptors like - Individual (like molecular weight, slogp,  H-Acceptor count, 
Xlogp, H-donor count, rotatble bond count, smr etc.), chi, chiV, path count, path cluster, 
polar surface area were calculated.  
Table 6: Some 2D molecular descriptor values 
 Activity Mol.wt. H-
Acceptor 
count 
Rotatable 
Bond 
count 
Slogp Smr Polarizabi-
lity AHC 
OA1.mol2 8.064 411.352 3 1 0.994 94.394 10.435 
OA10.mol2 8.737 438.354 4 2 0.436 102.49 17.992 
OA11.mol2 8.082 424.351 4 1 0.999 102.033 17.137 
OA12.mol2 9.004 466.365 5 3 0.399 106.42 21.493 
OA13.mol2 8.26 466.365 5 3 0.543 106.49 21.493 
OA14.mol2 8.069 424.351 4 1 1.143 102.103 17.137 
OA15.mol2 8.477 445.797 3 1 1.543 104.597 19.978 
OA16.mol2 8.006 438.354 4 2 0.58 102.56 17.992 
OA17.mol2 8.115 434.366 3 2 1.222 104.932 18.323 
OA18.mol2 9.832 454.354 5 3 0.388 102.977 18.796 
OA19.mol2 8.499 449.785 4 1 0.983 101.259 19.66 
OA2.mol2 8.368 426.343 4 1 0.661 99.16 16.924 
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OA20.mol2 9.86 470.353 6 3 -0.017 103.151 21.169 
OA21.mol2 9.271 442.343 5 2 0.02 99.221 17.696 
OA22.mol2 8.876 457.334 6 2 -0.464 97.489 16.687 
OA23.mol2 7.795 428.339 5 1 0.619 97.375 16.698 
OA24.mol2 9.991 469.345 6 3 0.475 100.626 17.738 
OA25.mol2 10.058 469.345 6 3 -0.096 101.245 17.759 
OA26.mol2 10.089 488.799 5 3 1.146 107.463 19.209 
OA27.mol2 9.516 488.799 5 3 0.605 108.001 20.758 
OA28.mol2 10.178 500.81 5 3 1.039 111.486 21.854 
OA29.mol2 10.669 477.368 5 3 0.636 108.578 19.112 
OA3.mol2 10.55 466.365 5 3 0.576 104.63 18.27 
OA30.mol2 8.576 456.8 3 1 1.637 106.685 17.637 
OA4.mol2 7.756 440.327 5 1 0.054 96.371 15.658 
OA5.mol2 8.804 466.365 5 3 0.866 105.612 19.953 
OA6.mol2 8.947 438.354 4 2 0.904 101.683 16.542 
OA7.mol2 7.329 424.351 4 1 1.106 100.444 17.055 
OA8.mol2 8.37 445.797 3 1 1.867 103.72 18.459 
OA9.mol2 9.341 445.797 3 1 1.399 104.527 19.978 
 
The invariable columns do not have any contribution to the model building and hence were 
removed. The Unicolumn statistics of the remaining columns were found to be as tabulated 
below. 
Table 7: Unicolumn Statistics 
Column name Average Maximum Minimum StdDev Sum 
ACTIVITY 
(Training Set) 
8.7857 10.6690 7.3290 0.8879 202.0720 
ACTIVITY 
(Test Set) 
9.3453 10.5500 8.0060 0.8980 65.4170 
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The maximum of Test Set was found to be less than the maximum of Training Set and minimum 
of Test Set was found to be less than the minimum of Training Set, which is in accordance with 
the set guidelines [36]. 
Four 2D models were generated by taking different Variable Selection Methods and Regression 
Methods.  
Table 7: Model equations of the four 2D models 
MODEL  MODEL EQUATION 
Model 1 ACTIVITY =  + 0.6205(± 0.0766) T_O_O_6 + 0.0901(± 0.0098) smr - 0.2053(± 
0.0502) T_T_N_3 - 0.0333(± 0.0030) T_2_C_5 - 0.1248(± 0.0506) T_C_Cl_3 + 
1.9346 
Model 2 ACTIVITY =  + 0.7055 T_O_O_6 + 0.0542 smr - 0.1498 T_T_N_3 - 0.0249 
T_2_2_4 + 3.7355 
Model 3 ACTIVITY = + 0.0637(± 0.0014) T_2_C_2 - 0.2422(± 0.0011) T_2_C_5 + 
0.2246(± 0.0219) T_2_C_0 - 0.4624(± 0.0252) T_T_Cl_2 - 1.7685(± 0.1287) 
T_T_N_0 - 0.1654(± 0.0034) T_C_O_4 + 0.0286(± 0.0046) polarizabilityAHC - 
0.3945(± 0.1112) T_O_O_2 + 0.0234(± 0.0020) 4PathCount + 0.1696(± 0.0007) 
T_2_T_7 + 7.8875 
Model 4 ACTIVITY =  + 0.0256 polarizabilityAHP + 0.0029 5PathCount - 0.3047 
T_T_N_7 - 0.0052 T_Cl_Cl_0 + 0.0879 4pathClusterCount + 0.6786 T_O_O_6 - 
0.0692 T_C_O_6 - 0.0454 T_2_2_2 + 0.0160 T_T_O_5 - 0.2454 T_2_Cl_1 + 
5.1757 
 
MODEL 1: 
ACTIVITY =  + 0.6205(± 0.0766) T_O_O_6 + 0.0901(± 0.0098) smr - 0.2053(± 0.0502) 
T_T_N_3 - 0.0333(± 0.0030) T_2_C_5 - 0.1248(± 0.0506) T_C_Cl_3 + 1.9346 
Ntrain =  23, Ntest = 7, Degree of freedom = 17, r
2
 = 0.9028,  q
2
 = 0.7860,  F_test = 31.5859,     
r
2
_se = 0.3149, q
2
_se = 0.4673, pred_r
2
 = 0.1483, pred_r
2
se = 0.9990
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The Model 1, with Multiple Regression Method and Forward-Backward Stepwise Variable 
Selection Method, has the coefficient of determination (r
2
) value of 0.9028. It shows cross-
validated squared correlation coefficient (q
2
 = 0.7860) of 79% and a predictivity for the external 
test set (pred_r
2
 = 0.1483) of 15%. The coefficient magnitude of a descriptor shows its relative 
contribution with respect to other descriptors and sign indicates whether it is directly or inversely 
proportional to the activity. In this QSAR model, the positive coefficient of T_O_O_6 and smr 
shows that an increase in the value of these descriptors enhances the activity. On the other hand, 
negative coefficients of T_T_N_3, T_2_C_5 and T_C_Cl_3 indicate that an increase in these 
descriptor values will decrease the activity of the compound.  
The descriptor T_O_O_6, which is the count of number of Oxygen atoms (single, double or 
triple bonded) separated from another Oxygen atom by 6 bonds, plays the most important role in 
the activity of the compound with a contribution of approximately 34%. The descriptor smr, 
which signifies the molecular refractivity which in turn is a measure of molecular size, 
contributes approximately 22% in determining the activity. T_T_N_3 (count of any atom 
separated from Nitrogen atom by 3 bonds), T_2_C_5 (count of any type of double bonded atom 
separated from Carbon atom by 5 bonds) and T_C_Cl_3 (count of  Carbon atom separated from 
Chlorine atom by 3 bonds) have negative contributions of approximately 18%, 15% and 12% 
respectively. 
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Figure 14: Fitness Plot of 2D QSAR Model 1 
 
Figure 15: Contribution Plot 2D QSAR Model 1 
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MODEL 2: 
ACTIVITY =  + 0.7055 T_O_O_6 + 0.0542 smr - 0.1498 T_T_N_3 - 0.0249 T_2_2_4 + 3.7355 
Ntrain =  23, Ntest = 7, Degree of freedom = 19, r
2
 = 0.8746, q
2
 = 0.8047,  F_test = 44.1556,     
r
2
_se = 0.3384, q
2
_se = 0.4223, pred_r
2
 = 0.2171, pred_r
2
se = 0.9578 
In model 2 (with Partial Least Square Regression and Forward-Backward Stepwise Variable 
Selection), the coefficient of determination (r
2
) value was computed to be 0.8746. It shows cross-
validated squared correlation coefficient (q
2
 = 0.8047) of 80% and a predictivity for the external 
test set (pred_r
2
 = 0.2171) of 22%. The positive coefficient of T_O_O_6 and smr indicate that an 
increase in these descriptors increases the activity and the negative coefficients of T_T_N_3 and 
T_2_2_4 imply that an increase in these descriptors will decrease the activity. According to this 
2D model, the descriptor T_O_O_6, the count of number of Oxygen atoms (single, double or 
triple bonded) separated from another Oxygen atom by 6 bonds, contributes to the activity by 
approximately 51% . The descriptor smr, which is the molecular refractivity which (a measure of 
molecular size), contributes approximately 17% in determining the activity. T_T_N_3(any atom 
separated from a Nitrogen atom by 3 bonds) and T_2_2_4 (any double bonded atom separated 
from another double bonded atom by 4 bonds) descriptors have negative contributions of 17% 
and 14% respectively.  
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Figure 16: Fitness Plot of 2D QSAR Model 2 
 
Figure 17: Contribution Plot of 2D QSAR Model 2 
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MODEL 3: 
ACTIVITY = + 0.0637(± 0.0014) T_2_C_2 - 0.2422(± 0.0011) T_2_C_5 + 0.2246(± 0.0219) 
T_2_C_0 - 0.4624(± 0.0252) T_T_Cl_2 - 1.7685(± 0.1287) T_T_N_0 - 0.1654(± 0.0034) 
T_C_O_4 + 0.0286(± 0.0046) polarizabilityAHC - 0.3945(± 0.1112) T_O_O_2 + 0.0234(± 
0.0020) 4PathCount + 0.1696(± 0.0007) T_2_T_7 + 7.8875 
Ntrain =  23, Ntest = 7, Degree_of_freedom = 12, r
2
 = 0.9720,  q
2
 = 0.6968,  F_test = 41.6574,  
r2_se = 0.2012, q2_se = 0.6620, pred_r2 = 0.5794, pred_r2se = 1.3604 
The Model 3, with Multiple Regression Method and Simulated Annealing Variable Selection 
Method, has the coefficient of determination (r
2
) value of 0.9720. It shows cross-validated 
squared correlation coefficient (q
2
 = 0.6968) of 70% and a predictivity for the external test set 
(pred_r
2
 = 0.5794) of 58%.  In this QSAR model, positive sign of T_2_C_2, T_2_C_0, 
polarizabilityAHC, 4PathCount and T_2_T_7 indicate that an increase in these descriptors 
increases the activity of the compound. On the other hand, negative sign of T_2_C_5, T_T_Cl_2, 
T_T_N_0, T_C_O_4 and T_O_O_2 signify that an increase in these descriptors decrease the 
activity of the compound. The descriptor T_2_C_2, the count of any double bonded atoms 
separated from Carbon atom by 2 bonds, contributes to the activity by 6%. The descriptor 
T_2_C_0, the count of any atom double bonded to Carbon atom, contributes to the activity by 
5%. The descriptor polarizabilityAHC, which is a measure of molecular polarizability has a 
contribution of approximately 1%. The descriptor 4PathCount, which signifies the number of 
fragments of fourth order, has a contribution of approximately 2%. The descriptor T_2_T_7, 
which is the count of double bonded atoms separated from any atom by 7 bonds, has a 
contribution of approximately 26%. The descriptors T_2_C_5 (count of double bonded atoms 
separated from Carbon atom by 5 bonds), T_T_Cl_2 (count of any atom separated from Chlorine 
atom by 2 bonds), T_T_N_0 (count of any atom bonded to Nitrogen atom), T_C_O_4 (count of 
Carbon atoms separated from Oxygen atoms by 4 bonds) and T_O_O_2 (count of oxygen atoms 
separated from oxygen atoms by 2 bonds) have negative contributions of approximately 27%, 
7%, 10%, 9% and 3% respectively. 
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Figure 18:  Fitness Plot of 2D QSAR Model 3 
 
Figure 17: Contribution Plot of 2D QSAR Model3 
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MODEL 4: 
ACTIVITY =  + 0.0256 polarizabilityAHP + 0.0029 5PathCount - 0.3047 T_T_N_7 - 0.0052 
T_Cl_Cl_0 + 0.0879 4pathClusterCount + 0.6786 T_O_O_6 - 0.0692 T_C_O_6 - 0.0454 
T_2_2_2 + 0.0160 T_T_O_5 - 0.2454 T_2_Cl_1 + 5.1757 
Ntrain =  23, Ntest = 7, Degree_of_freedom = 18, r
2
 =  0.9066,  q
2
 =  0.7292,  F_test = 43.6887,  
r2_se = 0.3000, q2_se = 0.5108, pred_r2 = 0.1095, pred_r2se = 1.0214 
The Model 4, with Partial Least Square Regression Method and Simulated Annealing Variable 
Selection Method, has the coefficient of determination (r
2
) value of 0.9066. It shows cross-
validated squared correlation coefficient (q
2
 = 0.7292) of 73% and a predictivity for the external 
test set (pred_r
2
 = 0.1095) of 11%.  In this QSAR model, positive sign of polarizabilityAHP, 
5PathCount, 4pathClusterCount, T_O_O_6 and T_T_O_5 signifies that an increase in these 
descriptors increases the activity of the compound. On the other hand, negative sign of 
T_T_N_7, T_Cl_Cl_0, T_O_O_6, T_C_O_6, T_2_2_2 and T_2_Cl_1 indicates that an increase 
in these descriptors decreases the activity of the compound. The descriptor polarizabilityAHP, 
which is a measure of molecular polarizability has a contribution of approximately 3%. The 
descriptor 5PathCount, which signifies the number of fragments of fifth order has a contribution 
of approximately 1%. The descriptor 4pathClusterCount, which signifies the number of 
fragments of fourth order pathcluster in a molecule, has a contribution of approximately 15%. 
The descriptor T_O_O_6, which is the count of oxygen atoms separated from other oxygen 
atoms by 6 bonds, has the highest contribution of approximately 32%. The descriptor T_T_O_5, 
which is the count of atoms separated from Oxygen atoms by 5 bonds, contributes by 
approximately 5%. The descriptors T_T_N_7 (count of atoms separated from Nitrogen atoms by 
7 bonds), T_Cl_Cl_0 (count of Chlorine atoms bonded to other Chlorine atoms), T_O_O_6 
(count of Oxygen atoms separated from other oxygen atoms by 6 bonds), T_C_O_6 (count of 
Carbon atoms separated from Oxygen atoms by 2 bonds), T_2_2_2 (count of any double bonded 
atom separated by 2 bonds from another double bonded atom) and T_2_Cl_1 (count of any 
double bonded atom separated from Chlorine atom by 1 bond) have negative contributions of 
approximately 17%, 1%, 11%, 11% and 4% respectively.  
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Figure 20: Fitness Plot of 2D QSAR Model 4 
 
Figure 21: Contribution Plot of 2D QSAR Model 4 
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Table 9: Comparison of actual and predicted activities by the four 2D models 
 ACTUAL 
ACTIVITY 
PREDICTED ACTIVITY 
MODEL 1 
SVS-Multiple 
MODEL 2 
SVS-PLS 
MODEL 3 
SA-Multiple 
MODEL 4 
SA-PLS 
OA1 8.064 8.476776 8.277796 8.021083 8.084438 
OA10 8.737 8.840085 8.592003 8.94967 8.940079 
OA11 8.082 8.24949 8.117734 8.224099 8.133052 
OA12 9.004 8.86114 8.730217 8.946995 8.814196 
OA13 8.26 8.600965 8.634371 8.436474 8.208163 
OA14 8.069 8.050457 7.971693 8.054514 7.951035 
OA15 8.477 8.59743 8.706183 8.516854 8.614481 
OA16 8.006 8.779773 8.595796 8.484526 8.344126 
OA17 8.115 8.560521 8.549969 7.851887 8.381672 
OA18 9.832 9.725277 9.605908 9.977982 9.572596 
OA19 8.499 8.288088 8.25126 8.395888 8.108822 
OA2 8.368 8.240208 8.112658 8.535434 8.070947 
OA20 9.86 9.641073 9.565545 9.891581 9.615666 
OA21 9.271 9.686639 9.55188 9.361893 9.557436 
OA22 8.876 9.197432 9.308563 8.709558 9.401059 
OA23 7.795 7.596499 7.715855 7.546839 7.749213 
OA24 9.991 9.513385 9.652873 10.153558 9.418901 
OA25 10.058 9.236069 9.362591 9.324864 9.416218 
OA26 10.089 9.855186 10.073222 9.973872 9.86731 
OA27 9.516 9.928493 9.878163 9.588648 9.986058 
OA28 10.178 10.375833 10.415754 10.135028 10.410219 
OA29 10.669 10.296707 10.258167 10.560922 10.356189 
OA3 10.55 8.499992 8.458874 7.49751 8.251962 
OA30 8.576 8.818928 8.844243 8.900804 8.881285 
OA4 7.756 7.655735 7.812062 7.875785 7.904668 
OA5 8.804 8.488567 8.51209 7.83472 8.757123 
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OA6 8.947 8.567444 8.423695 8.905662 8.677034 
OA7 7.329 7.362441 7.58247 7.449547 7.71957 
OA8 8.37 8.285169 8.534082 8.423659 8.463124 
OA9 9.341 8.840709 8.70239 9.148885 9.101206 
 
 
Table 10: Statistical values of the 2D models 
STATISTICAL 
VALUES 
MODEL1 MODEL2 MODEL 3 MODEL4 
 N  23  23  23  23 
 Degree of freedom  17  19  12  18 
 r
2 
 0.9028  0.8746  0.9720  0.9066 
 q
2 
 0.7860  0.8047  0.6968  0.7292 
 F_test  31.5859  44.1556  41.6574  43.6887 
 r
2
_se  0.3149  0.3384  0.2012  0.3000 
 q
2
_se  0.4673  0.4223  0.6620  0.5108 
 pred_r
2 
 0.1483  0.2171  0.5794  0.1095 
 pred_r
2
se  0.9990  0.9578  1.3604  1.0214 
 
According to VlifeMDS set guidelines, QSAR models are significant if r
2 
> 0.7, q
2
 > 0.5 and 
pred_r
2
 > 0.5. Thus comparing the statistical parameters of the four 2D QSAR models, we can 
consider the 3
rd
 model to be statistically the best model.  
 
4.4.2 ALIGNMENT OF MOLECULES 
The molecules after molecular alignment were opened in VLifeMDS simultaneously.  
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  Figure 22: Aligned molecules w.r.t the skeleton structure. 
4.4.3 3D QSAR 
3D QSAR was performed using the “3D QSAR” module of VlifeMDS software. 3D descriptors 
were computed by calculating the electrostatic and steric molecular fields. Some 3D descriptor 
values and the Unicolumn statistics of the data set are tabulated below. 
Table 11: Some 3D descriptor values 
 ACTIVITY E_1 E_2 E_3 S_1 S_2 S_3 S_4 
OA1.mol2 8.064 -0.166 -0.236 -0.269 -0.011 -0.016 -0.018 -0.016 
OA10.mol2 8.737 -0.139 -0.193 -0.218 -0.013 -0.019 -0.022 -0.019 
OA11.mol2 8.082 -0.196 -0.274 -0.31 -0.012 -0.017 -0.019 -0.017 
OA12.mol2 9.004 -0.156 -0.226 -0.259 -0.013 -0.019 -0.022 -0.019 
OA13.mol2 8.26 -0.167 -0.24 -0.273 -0.011 -0.016 -0.019 -0.016 
OA14.mol2 8.069 -0.193 -0.269 -0.303 -0.011 -0.016 -0.018 -0.016 
OA15.mol2 8.477 -0.209 -0.287 -0.322 -0.011 -0.016 -0.018 -0.016 
OA16.mol2 8.006 -0.184 -0.258 -0.292 -0.011 -0.016 -0.018 -0.016 
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OA17.mol2 8.115 -0.192 -0.268 -0.302 -0.011 -0.016 -0.018 -0.016 
OA18.mol2 9.832 -0.216 -0.295 -0.331 -0.011 -0.016 -0.018 -0.016 
OA19.mol2 8.499 -0.227 -0.307 -0.344 -0.011 -0.016 -0.018 -0.016 
OA2.mol2 8.368 -0.238 -0.319 -0.356 -0.011 -0.016 -0.018 -0.016 
OA20.mol2 9.86 -0.231 -0.312 -0.348 -0.011 -0.016 -0.018 -0.016 
OA21.mol2 9.271 -0.212 -0.291 -0.327 -0.011 -0.016 -0.018 -0.016 
OA22.mol2 8.876 -0.306 -0.413 -0.461 -0.012 -0.017 -0.019 -0.017 
OA23.mol2 7.795 -0.265 -0.366 -0.412 -0.012 -0.017 -0.019 -0.017 
OA24.mol2 9.991 -0.15 -0.219 -0.251 -0.012 -0.017 -0.02 -0.017 
OA25.mol2 10.058 -0.271 -0.352 -0.388 -0.008 -0.011 -0.012 -0.011 
OA26.mol2 10.089 -0.277 -0.38 -0.427 -0.012 -0.017 -0.019 -0.017 
OA27.mol2 9.516 -0.172 -0.238 -0.269 -0.011 -0.016 -0.019 -0.016 
OA28.mol2 10.178 -0.139 -0.201 -0.229 -0.011 -0.016 -0.019 -0.016 
OA29.mol2 10.669 -0.162 -0.225 -0.254 -0.01 -0.014 -0.016 -0.014 
OA3.mol2 10.55 0.101 0.15 0.174 -0.014 -0.022 -0.025 -0.022 
OA30.mol2 8.576 -0.168 -0.24 -0.273 -0.011 -0.016 -0.019 -0.016 
OA4.mol2 7.756 -0.266 -0.355 -0.396 -0.011 -0.017 -0.019 -0.017 
OA5.mol2 8.804 0.065 0.1 0.119 -0.017 -0.026 -0.031 -0.026 
OA6.mol2 8.947 -0.083 -0.105 -0.114 -0.014 -0.02 -0.024 -0.02 
OA7.mol2 7.329 -0.145 -0.198 -0.221 -0.012 -0.017 -0.019 -0.017 
OA8.mol2 8.37 -0.132 -0.18 -0.201 -0.011 -0.016 -0.018 -0.016 
OA9.mol2 9.341 -0.225 -0.311 -0.35 -0.011 -0.016 -0.019 -0.016 
 
Table 12: Unicolumn statistics 
Column name Average Maximum Minimum StdDev Sum 
ACTIVITY 
(Training Set) 
9.0171 10.6690 7.3290 0.9332 234.445 
ACTIVITY 
(Test Set) 
8.2610 8.4770 8.0820 0.1931 33.004 
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Descriptors that contribute to the model are S_349 and S_7. The range of S_349 is from -0.5905 
to -0.5388 while the range of S_7 is from -0.0532 to -0.0346. A negative range of steric fields 
indicates that negative steric potential is favorable for an increase in the activity, and hence less 
bulky substituent group is preferred in that region.  
k-Nearest Neighbour = 3, Ntest = 4, Ntraining = 26, Degree of freedom = 23, q
2
 = 0.6548, q
2
se = 
0.5483, pred_r
2 
= 0.8999, pred_r
2
se = 0.2829 
According to the model, the internal model validation predicts the activity of training set as 65% 
(q
2 
= 0.6548) and external model validation predicts the activity of the test set as 90% (pred_r
2
 = 
0.8999). 
 
Figure 23: 3D QSAR model 
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Figure 24: Steric molecular fields determined by the 3D model 
 
 
Figure 25: Fitness Plot of 3D Model 
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The activities of the molecules, as predicted by the 3D QSAR model, are as below – 
Table 13: Comparison of actual and predicted activities by 3D QSAR model 
MOLECULE ACTUAL 
ACTIVITY 
PREDICTED 
ACTIVITY 
OA1 8.064 8.802181 
OA10 8.737 8.583205 
OA11 8.082 7.625713 
OA12 9.004 8.494189 
OA13 8.26 8.737086 
OA14 8.069 8.043555 
OA15 8.477 8.311277 
OA16 8.006 8.064338 
OA17 8.115 8.146974 
OA18 9.832 9.864937 
OA19 8.499 8.415672 
OA2 8.368 7.943678 
OA20 9.86 10.262446 
OA21 9.271 8.399911 
OA22 8.876 8.531852 
OA23 7.795 8.414827 
OA24 9.991 9.812584 
OA25 10.058 9.972453 
OA26 10.089 9.779635 
OA27 9.516 9.970558 
OA28 10.178 10.151561 
OA29 10.669 10.189832 
OA3 10.55 10.032097 
OA30 8.576 8.389818 
OA4 7.756 8.147806 
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OA5 8.804 8.896068 
OA6 8.947 8.513603 
OA7 7.329 8.570383 
OA8 8.37 8.31226 
OA9 9.341 7.899583 
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CHAPTER 5: 
CONCLUSION 
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CONCLUSIONS: 
In our current study, we tried to narrow down our search for modulators that can promote the 
effect of NGF by binding to its receptor, and thus be used as therapeutic tools to supplement 
enhanced nerve regeneration. Based on our docking results, the best docked ligand was 
kaempferol-3-glucoside. However, due to its poor ADME properties, we performed further 
studies with the next set of molecules having equally good binding affinity with the receptor. 
With binding energy of approximately -9 kcal/mol, all these molecules were found to have a 
structure similar to triterpenoids. These molecules were found to be oleanolic acid, taraxerone, 
taraxerol, alpha and beta amyrin. These molecules were also found to have suitable ADME 
properties to be considered as candidate drug molecules. We further generated mathematical 
models using 2D and 3D Quantitative Structure-Activity Relationship(QSAR) to establish a 
relationship between the structure and activity. For this, we chose oleanolic acid as the skeleton 
structure and its derivatives were designed. The 2D and 3D models generated, provide us an 
efficient way to predict the activity of any new analog with similar structures or design a new 
molecule with better activity.  
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